Results 11 to 20 of about 6,442 (216)

Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia [PDF]

Journal of Market Access & Health Policy, 2021
Background Standard of care (SoC) for transfusion-dependent β-thalassemia (TDT) requires lifelong, regular blood transfusions as well as chelation to reduce iron accumulation.
Anuraag R. Kansal, Odette S. Reifsnider, Sarah B. Brand, Neil Hawkins, Anna Coughlan, Shujun Li, Lael Cragin, Clark Paramore, Andrew C. Dietz, J. Jaime Caro   +9 more
doaj   +2 more sources

Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancerResearch in context

EBioMedicine, 2019
Background: Bromodomain and extra-terminal inhibitors (BETi) have shown efficacy for the treatment of aggressive triple negative breast cancer (TNBC).
Sushmita Mustafi, Vladimir Camarena, Rehana Qureshi, Hyunho Yoon, Claude-Henry Volmar, Tyler C. Huff, David W. Sant, Lihong Zheng, Shaun P. Brothers, Claes Wahlestedt, Joyce Slingerland, Gaofeng Wang   +11 more
doaj   +2 more sources

El acuerdo Beti: frontón Beti Jai

, 2014
El acuerdo Beti: frontón Beti ...
López Sánchez-Vegazo, Ana
openaire   +2 more sources

Primary Pulmonary NUT Carcinoma: A Case Illustration of Therapeutic Challenges and Review of Emerging Targeted Therapies. [PDF]

Case Rep Oncol Med
Background Pulmonary NUT carcinoma is a rare but highly aggressive malignancy with poor prognosis. It typically affects younger patients with no smoking history. Given its rapid progression, it is crucial to consider it as a differential diagnosis in a poorly differentiated thoracic mass to ensure timely diagnosis and management.
Bae JY, Gao XY, Dermawan JK, Hellyer JA.
europepmc   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107. [PDF]

Mol Oncol
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Schmitz J, Bartkowiak AL, Rose M, Kolks N, Petzsch P, Solanki V, Stoffel A, Faßbender B, Lepping L, Volkamer J, Köhrer K, Seifert M, Mahmoudi T, Zuiverloon TCM, Niegisch G, Hoffmann MJ.   +15 more
europepmc   +2 more sources

Oxygen reduction reaction on platinum single-crystal electrodes modified with protonic ionic liquid

Electrochemistry Communications, 2022
The oxygen reduction reaction (ORR) on the low- and high-index planes of Pt modified with a protonic ionic liquid ([7-methyl-1,5,7-triazabicyclo(4.4.0)dec-5-ene][bis(pentafluoroethylsulfonyl)imide], referred to here as [MTBD][beti]) was studied in 0.1 M ...
Rui Suzuki, Masashi Nakamura, Nagahiro Hoshi   +2 more
doaj   +1 more source

Targeting radioresistance and replication fork stability in prostate cancer

JCI Insight, 2022
The bromodomain and extraterminal (BET) family of chromatin reader proteins bind to acetylated histones and regulate gene expression. The development of BET inhibitors (BETi) has expanded our knowledge of BET protein function beyond transcriptional ...
Xiangyi Li, GuemHee Baek, Suzanne Carreira, Wei Yuan, Shihong Ma, Mia Hofstad, Sora Lee, Yunpeng Gao, Claudia Bertan, Maria de los Dolores Fenor de la Maza, Prasanna G. Alluri, Sandeep Burma, Benjamin P.C. Chen, Ganesh V. Raj, Johann de Bono, Yves Pommier, Ram S. Mani   +16 more
doaj   +1 more source

A Novel Acetylation-Immune Subtyping for the Identification of a BET Inhibitor-Sensitive Subgroup in Melanoma

Pharmaceuticals, 2023
Background: There have been significant advancements in melanoma therapies. BET inhibitors (BETis) show promise in impairing melanoma growth. However, identifying BETi-sensitive melanoma subtypes is challenging.
Liuying Wang, Liuchao Zhang, Shuang Li, Lei Cao, Kang Li, Weiwei Zhao   +5 more
doaj   +1 more source

The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53

Neoplasia: An International Journal for Oncology Research, 2021
Amplification of MYCN is a poor prognostic feature in neuroblastoma (NBL) indicating aggressive disease. We and others have shown BET bromodomain inhibitors (BETi) target MYCN indirectly by downregulating its transcription.
Joanna S. Yi, Oscar Sias-Garcia, Nicole Nasholm, Xiaoyu Hu, Amanda Balboni Iniguez, Matthew D. Hall, Mindy Davis, Rajarshi Guha, Myrthala Moreno-Smith, Eveline Barbieri, Kevin Duong, Jessica Koach, Jun Qi, James E. Bradner, Kimberly Stegmaier, William A. Weiss, W. Clay Gustafson   +16 more
doaj   +1 more source

Concurrent targeting of MAP3K3 and BRD4 by miR-3140-3p overcomes acquired resistance to BET inhibitors in neuroblastoma cells

Molecular Therapy: Nucleic Acids, 2021
Neuroblastoma (NB) harboring MYCN amplification is a refractory disease with a poor prognosis. As BRD4, an epigenetic reader belonging to the bromodomain and extra terminal domain (BET) family, drives transcription of MYCN in NB cells, BET inhibitors ...
Chang Liu, Yasuyuki Gen, Kousuke Tanimoto, Tomoki Muramatsu, Jun Inoue, Johji Inazawa   +5 more
doaj   +1 more source